Virtual Reality During Procedures in Pediatric Patients
|ClinicalTrials.gov Identifier: NCT03686176|
Recruitment Status : Enrolling by invitation
First Posted : September 26, 2018
Last Update Posted : September 18, 2019
Pediatric emergency rooms and hospitals are anxiety provoking and often painful places for pediatric patients and families. Children, ages 1 day to 22 years, present to the Johns Hopkins emergency room and are admitted to the hospital for a wide range of medical conditions, many of which require medical interventions. Many of these interventions are the source of anxiety and pain, including burn debridement or dressing changes, laceration repair, or intravenous (IV) line placement. In order to mitigate anxiety and pain; sedation, distraction, child life support, analgesia, and other methods are routinely employed. Medical anxiolysis and analgesia are often effective, typically using benzodiazepines, opiates, and/or ketamine, however these medications include risks and side effects. Also, with the growing opioid epidemic, there is a shift in clinical practice to decrease the reliance on narcotics. Thus, there is a growing urgency for non-narcotic methods of pain and anxiety reduction.
As an adjunct to the existing methods of anxiolysis and analgesia, non-invasive virtual reality (VR) therapy is showing promise as a means of distraction and coping with various medical procedures. The user is transported into a relaxing/distracting VR environment that diverts user's attention away from pain and anxiety. VR has demonstrated efficacy in the reduction of pain and anxiety experienced by individuals undergoing anxiety and pain inducing procedures. Based on existing data in adults and small pediatric populations, the investigators believe that the use of virtual reality simulations and games will decrease pediatric patient pain and anxiety related to painful procedures across multiple hospital settings and procedure types. Virtual reality therapy may also lead to decreased use of opiates, increased patient safety, no increase in procedure time, improved perceived procedure tolerance, and overall increase in patient and parent satisfaction. VR therapy has the potential to revolutionize the standard of care in pediatric procedural anxiolysis and analgesia.
While there is early data from small or narrow populations that show some improvement in pain and anxiety with VR use during pediatric procedures, some studies show no improvement. The investigators propose to fill this gap in the literature with a randomized, controlled, un-blinded study of virtual reality simulation compared to standard care in pediatric patients undergoing painful medical procedures.
|Condition or disease||Intervention/treatment||Phase|
|Virtual Reality Pediatrics||Other: Virtual Reality||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||176 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||randomized, unblinded, controlled|
|Masking:||None (Open Label)|
|Official Title:||Virtual Reality During Procedures in Pediatric Patients|
|Actual Study Start Date :||July 5, 2019|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||May 2021|
Experimental: Virtual Reality Group (Study Group)
In this arm, patients will receive standard of care plus may use virtual reality simulation goggles during a qualifying medical procedure.
Other: Virtual Reality
A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
Other Name: Oculus Go
No Intervention: Standard Care (Control Group)
In this arm, patients will receive standard of care during a qualifying medical procedure.
- Patient-reported Pain during the procedure [ Time Frame: Immediately post-procedure (15minutes) ]Pain described on visual analog scale (0-10), or Wong-Faces Scale (0-10) with 0 being no pain and 10 being worst pain.
- Anxiety as assessed by the subjective units of distress scale [ Time Frame: Immediately post-procedure (15minutes) ]The Subjective Units of Distress scale will be used to measure anxiety of subjects after procedures. This is a scale of 0-10 with 0 being no anxiety and 10 being maximum anxiety.
- Duration of procedure [ Time Frame: Immediately post-procedure (15minutes) ]Duration of procedure in minutes will be assessed for each procedure.
- Dosage of adjunct medications [ Time Frame: Immediately post-procedure (15minutes) ]Dosage of medications in mg given for pain will be measured.
- Tolerance of procedure as assessed by a Likert scale [ Time Frame: Immediately post-procedure (15minutes) ]Tolerance of procedure will be assessed using a Likert scale completed by procedurist, child life, parent. The Likert scale ranges from 1-5 with 1 being the least tolerable and 5 being most tolerable.
- Ease of completing procedure as assessed by a Likert scale [ Time Frame: Immediately post-procedure (15minutes) ]Ease of completing procedure will be assessed by a Likert scale which will be completed by procedurist. The scale ranges from 1-5 with 1 being difficult and 5 being easiest.
- Personnel use for immobilization [ Time Frame: Immediately post-procedure (15minutes) ]This will be assessed using number of people needed to immobilize a subject, Likert scale of level of pressure applied, and wrapping during a procedure. The Likert scale ranges from 1-5 with 1 being least amount of pressure applied and 5 being maximum amount of pressure applied.
- Number of IV or phlebotomy attempts [ Time Frame: Immediately post-procedure (15minutes) ]Number of IV or phlebotomy attempts until success will be counted(1, 2, 3, etc)
- Cybersickness as assessed by the simulator Sickness Questionnaire [ Time Frame: Immediately post-procedure (15minutes) ]The presence of Cybersickness after a procedure will be assessed using the simulator Sickness Questionnaire. The questionnaire has 16 symptoms with each symptom being scored from 0-3. This will yield scores ranging from 0 to 48 with higher scores being higher severity of Cybersickness.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03686176
|United States, Maryland|
|Johns Hopkins Children's Center|
|Baltimore, Maryland, United States, 21212|
|Principal Investigator:||Therese Canares, MD||Johns Hopkins University|